Vaxcell-Bio - Public Comps and Valuation Multiples

Vaxcell-Bio Overview

About Vaxcell-Bio

Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.

Founded

2010

HQ

Employees

n/a

Website

vaxcell-bio.com

Sectors

Vaccines & Immunotherapies
BioTech

Financials

Last FY Revenue $1.3M

Last FY EBITDA -$6.1M

EV

$147M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Vaxcell-Bio Financials

See Vaxcell-Bio valuation multiples based on analyst estimates

Vaxcell-Bio P&L

In the most recent fiscal year, Vaxcell-Bio reported revenue of $1.3M and EBITDA of -$6.1M.

Vaxcell-Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Vaxcell-Bio valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$1.3M	XXX	XXX	XXX
Gross Profit	XXX	$0.2M	XXX	XXX	XXX
Gross Margin	XXX	19%	XXX	XXX	XXX
EBITDA	XXX	-$6.1M	XXX	XXX	XXX
EBITDA Margin	XXX	-470%	XXX	XXX	XXX
EBIT	XXX	-$10.2M	XXX	XXX	XXX
EBIT Margin	XXX	-792%	XXX	XXX	XXX
Net Profit	XXX	-$7.2M	XXX	XXX	XXX
Net Margin	XXX	-559%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Vaxcell-Bio including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Vaxcell-Bio achieved $1.3M in revenue and -$6.1M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$1.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$0.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	19.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$6.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	-470.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$10.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	-791.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$7.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	-559.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Vaxcell-Bio

This financial data table provides comprehensive performance metrics for Vaxcell-Bio, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Vaxcell-Bio reported $1.3M in total revenue.
Fiscal year EBITDA was -$6.1M.
The company maintained a gross profit margin of 19.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was -470.4%.
Net profit margin reached -559.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Vaxcell-Bio. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Vaxcell-Bio Stock Performance

Vaxcell-Bio has current market cap of KRW 240B (or $163M), and EV of KRW 217B (or $147M).

Market Cap Evolution

Vaxcell-Bio Stock Data

As of December 4, 2025, Vaxcell-Bio's stock price is KRW 10350 (or $7).

See Vaxcell-Bio trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$147M	$163M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Vaxcell-Bio Valuation Multiples

Vaxcell-Bio's trades at 114.0x EV/Revenue multiple, and -24.2x EV/EBITDA.

See valuation multiples for Vaxcell-Bio and 15K+ public comps

Vaxcell-Bio Financial Valuation Multiples

As of December 4, 2025, Vaxcell-Bio has market cap of $163M and EV of $147M.

Equity research analysts estimate Vaxcell-Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vaxcell-Bio's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$163M	XXX	$163M	XXX	XXX	XXX
EV (current)	$147M	XXX	$147M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	114.0x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-24.2x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-14.4x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-22.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-14.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vaxcell-Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Vaxcell-Bio Margins & Growth Rates

Vaxcell-Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Vaxcell-Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vaxcell-Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Vaxcell-Bio and other 15K+ public comps

Vaxcell-Bio Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-470%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	108%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	318%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	811%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial